Welcome to our dedicated page for Cassava Sciences news (Ticker: SAVA), a resource for investors and traders seeking the latest updates and insights on Cassava Sciences stock.
Cassava Sciences, Inc. (SAVA) is a clinical-stage biotechnology company pioneering Alzheimer's disease research through therapeutic candidate simufilam and diagnostic tool SavaDx. This page aggregates official press releases, regulatory updates, and material event announcements directly from the company and verified sources.
Investors and researchers will find timely updates on Phase 3 clinical trial progress, FDA communications, intellectual property developments, and peer-reviewed study publications. Our curated feed ensures access to SAVA's critical milestones in drug development and diagnostic innovation without promotional commentary.
Key content categories include clinical trial results, partnership announcements with research institutions, financial disclosures related to R&D funding, and scientific presentations at major medical conferences. All materials are organized chronologically to track the company's evolving research narrative.
Bookmark this page for streamlined monitoring of Cassava Sciences' advancements in Alzheimer's therapeutics. For comprehensive analysis, cross-reference updates with SEC filings and scientific publications linked in source materials.
Cassava Sciences, focused on Alzheimer’s disease, announced that Remi Barbier, President & CEO, will present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York on May 2nd at 3 PM Eastern time. This event provides a platform for the company to engage with institutional investors through one-on-one meetings. Investors can access the live webcast here and the archived replay here. Cassava Sciences aims to innovate treatments for neurodegenerative diseases by stabilizing key brain proteins, although none of their products have been approved by regulatory authorities.
